Skip to main content
Home > The Daily Extra > Clinical News

Chronological Index of : Clinical News

 Current Issue
  • CLINICAL NEWS: Egalet jumps on data for abuse-deterrent morphine

    Egalet Corp. (NASDAQ:EGLT) climbed $1.18 (24%) to $6.11 on topline data from a human abuse liability study showing that 60 mg Egalet-001, an abuse-deterrent, extended-release, oral formulation of morphine, demonstrated …

    Published on 1/22/2015
  • CLINICAL NEWS: AZ's long-term Brilinta thinking

    AstraZeneca plc (LSE:AZN; NYSE:AZN) said anticoagulant Brilinta ticagrelor met the primary endpoint in a cardiovascular (CV) outcomes study evaluating long-term use of the drug beyond one year.AZ said twice-daily dosing…

    Published on 1/14/2015
  • CLINICAL NEWS: BMS's kingly Opdivo NSCLC data

    Bristol-Myers Squibb Co. (NYSE:BMY) said it ended the Phase III CheckMate -017 trial of Opdivo nivolumab to treat advanced or metastatic squamous cell non-small cell lung cancer (NSCLC) after an independent data …

    Published on 1/12/2015
  • CLINICAL NEWS: Argos falls on Phase IIb miss in HIV

    Argos Therapeutics Inc. (NASDAQ:ARGS) plunged $3.10 (32%) to $6.51 on Friday after reporting that AGS-004 missed the primary endpoint of a 1.1 log reduction in median viral load after 12 weeks of antiretroviral therapy …

    Published on 1/9/2015
  • CLINICAL NEWS: Once-every-four-weeks alirocumab meets in Phase III study

    Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported data from the first trials assessing once-every-four-weeks doses of alirocumab (REGN727, SAR236553) to treat hypercholesterolemia…

    Published on 1/9/2015
  • CLINICAL NEWS: Portola's Factor Xa antidote meets Phase III endpoint

    Portola Pharmaceuticals Inc. (NASDAQ:PTLA) gained $2.01 to $30.33 on Friday after its andexanet alfa met the primary endpoint in the first part of the Phase III ANNEXA-R study to reverse the anticoagulant activity of …

    Published on 1/9/2015
  • CLINICAL NEWS: Bind gains after NSCLC update

    Bind Therapeutics Inc. (NASDAQ:BIND) jumped $1.91 (37%) to $7.06 on Thursday after reporting it had enrolled the first patient in a Phase II study of BIND-014 to treat non-small cell lung cancer (NSCLC) patients with a …

    Published on 1/8/2015
  • CLINICAL NEWS: Biogen reports mixed Phase II results for LINGO antibody

    Biogen Idec Inc. (NASDAQ:BIIB) said BIIB033 did not meet its primary or secondary endpoints in the Phase II RENEW trial to treat acute optic neuritis (AON) but termed the results "encouraging" by providing the first …

    Published on 1/8/2015
  • CLINICAL NEWS: GW's epilepsy timetable eclipses Sativex cancer miss

    Investors ignored a Phase III trial miss for Sativex in cancer pain on Thursday, pushing up shares of GW Pharmaceuticals plc (NASDAQ:GWPH; LSE:GWP) by 13% on NASDAQ after the company said it expects to begin reading out…

    Published on 1/8/2015
  • CLINICAL NEWS: Neurocrine jumps on Phase III endometriosis data

    Neurocrine Biosciences Inc. (NASDAQ:NBIX) jumped $5.60 (26%) to $27.48 on Thursday after partner AbbVie Inc. (NYSE:ABBV) said elagolix (ABT-620) met its co-primary endpoints in the Phase III M12-665 trial to treat …

    Published on 1/8/2015
  • CLINICAL NEWS: Arena surges on Phase I data for S1PR1 candidate

    Arena Pharmaceuticals Inc. (NASDAQ:ARNA) added $2.53 (76%) to $5.85 on Wednesday, increasing its market cap to $1.3 billion, after reporting top-line results of a Phase Ib study of APD334, a sphingosine 1-phosphate …

    Published on 1/7/2015
  • CLINICAL NEWS: New high for Alkermes on Phase II schizophrenia data

    Alkermes plc (NASDAQ:ALKS) hit a 52-week high on Wednesday, jumping $5.82 (10%) to $66.75 after its ALKS 3831, a combination of olanzapine plus samidorphan, met the primary endpoint of equivalence to olanzapine in …

    Published on 1/7/2015
  • CLINICAL NEWS: Zafgen climbs on Phase II HIAO results

    Zafgen Inc. (NASDAQ:ZFGN) gained $6.65 (21%) to $38.31 after it said beloranib met the primary endpoint of weight reduction in a Phase II trial to treat adults with hypothalamic injury associated obesity (HIAO). In the …

    Published on 1/7/2015
  • CLINICAL NEWS: KaloBios drops CF progam after Phase II miss

    KaloBios Pharmaceuticals Inc. (NASDAQ:KBIO) said it would discontinue development of KB001-A in cystic fibrosis after the compound failed a Phase II study in CF patients with Pseudomonas aeruginosa lung infections. The …

    Published on 1/6/2015
  • CLINICAL NEWS: BrainStorm spikes on NurOwn data in ALS

    BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) said a single dose of its NurOwn stem cell therapy slowed at least one measure of disease progression in 11 of 12 of patients in a Phase IIa trial to treat ALS.The company…

    Published on 1/5/2015
  • CLINICAL NEWS: Cempra looking for $100M on back of solithromycin data

    Cempra Inc. (NASDAQ:CEMP) said its oral solithromycin (CEM-101) met the primary endpoint in the Phase III Solitaire-Oral trial to treat community acquired bacterial pneumonia (CABP) and proposed to raise up to $100 …

    Published on 1/5/2015
  • CLINICAL NEWS: Achillion gains on HCV data

    Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) gained $1.28 to $15.49 on Monday after it said 100% of patients receiving ACH-3102 plus Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) achieved an SVR4 after six …

    Published on 12/22/2014
  • CLINICAL NEWS: Radius jumps on Phase III osteoporosis data

    Radius Health Inc. (NASDAQ:RDUS) gained $5.42 (17%) to $37.45 after abaloparatide-SC met the primary endpoint of a Phase III study to reduce fractures in postmenopausal osteoporosis.In the ACTIVE trial, abaloparatide-SC…

    Published on 12/22/2014
  • CLINICAL NEWS: Roche down on Phase III setbacks

    Roche (SIX:ROG; OTCQX:RHHBY) fell CHF18.30 to CHF270.40 on Friday after reporting disappointing data from a Phase III trial of breast cancer drug Kadcyla ado-trastuzumab emtansine and discontinuing a Phase III study of …

    Published on 12/19/2014
  • CLINICAL NEWS: GSK, Agenus shingles vaccine meets primary endpoint

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said its HZ/su herpes zoster vaccine (GSK1437173A) met the primary endpoint of reducing the risk of shingles by 97.2% in people aged 50 and older vs. placebo in the Phase III ZOE-…

    Published on 12/18/2014
  • CLINICAL NEWS: Tetraphase climbs on Phase III cIAI data

    Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) jumped $4.81 (14%) to $38 on Thursday after IV eravacycline met the primary endpoint in the Phase III IGNITE 1 trial to treat complicated intra-abdominal infection (cIAI). …

    Published on 12/18/2014
  • CLINICAL NEWS: Well-traveled desmoteplase finally hits the wall

    H. Lundbeck A/S (CSE:LUN) said it will cease development of desmoteplase (DPSA) to treat acute ischemic stroke.The compound, which has been in development for more than a decade and failed a Phase III study in 2007, …

    Published on 12/17/2014
  • CLINICAL NEWS: ALA to promote Lung-MAP

    The American Lung Association said it will promote the Lung-MAP project, a "master protocol" trial designed to evaluate several compounds simultaneously to treat squamous cell lung cancer.Under a partnership with the …

    Published on 12/16/2014
  • CLINICAL NEWS: Cyclacel plummets on futility analysis

    Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) dropped $2.15 (76%) to $0.68 after oral sapacitabine (CYC682) failed a futility analysis of survival in a Phase III trial to treat acute myelogenous leukemia (AML).The Data …

    Published on 12/16/2014
  • CLINICAL NEWS: Alnylam outlines R&D strategy

    At its R&D day on Friday, Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) refined its focus on developing RNAi therapeutics across three areas: hepatic infectious disease, genetic medicines and cardiometabolic disease. The …

    Published on 12/12/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993